Human Insulin Drugs Market by Product Type, Brands, Drugs, Delivery Devices, Application

Description

List of Tables

The Global Human Insulin Drugs Market is forecasted to grow significantly, with a projected USD 50.92 billion in 2023 at a CAGR of 10.66% and expected to reach a staggering USD 103.97 billion by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Human Insulin Drugs Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Human Insulin Drugs Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Product Type, market is studied across Basal or Long-Acting Insulins, Biosimilar Insulins, Combination Insulins, Fast-Acting Insulins, and Traditional Human Insulins. The Traditional Human Insulins is projected to witness significant market share during forecast period.

Based on Brands, market is studied across Humalog, Lantus, and NovoRapid. The Lantus is projected to witness significant market share during forecast period.

Based on Drugs, market is studied across Biologics and Biosimilars. The Biosimilars is projected to witness significant market share during forecast period.

Based on Delivery Devices, market is studied across Pen Needles, Pens, and Syringes. The Syringes is projected to witness significant market share during forecast period.

Based on Application, market is studied across Type 1 Diabetes and Type 2 Diabetes. The Type 1 Diabetes is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 38.75% in 2022, followed by Europe, Middle East & Africa.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Human Insulin Drugs Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Human Insulin Drugs Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Human Insulin Drugs Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Human Insulin Drugs Market?

4. What is the competitive strategic window for opportunities in the Global Human Insulin Drugs Market?

5. What are the technology trends and regulatory frameworks in the Global Human Insulin Drugs Market?

6. What is the market share of the leading vendors in the Global Human Insulin Drugs Market?

7. What modes and strategic moves are considered suitable for entering the Global Human Insulin Drugs Market?

Product Code: MRR-957C47F9223E

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. Human Insulin Drugs Market, by Product Type, 2022 vs 2030
4.3. Human Insulin Drugs Market, by Brands, 2022 vs 2030
4.4. Human Insulin Drugs Market, by Drugs, 2022 vs 2030
4.5. Human Insulin Drugs Market, by Delivery Devices, 2022 vs 2030
4.6. Human Insulin Drugs Market, by Application, 2022 vs 2030
4.7. Human Insulin Drugs Market, by Region, 2022 vs 2030

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Rising prevalence of dibetic patient all over the globe
  - 5.1.1.2. Significant growth of geriatric and obese population
  - 5.1.1.3. Adoption of different drug delivery methods
- 5.1.2. Restraints
  - 5.1.2.1. High cost associated with human insulin drugs
- 5.1.3. Opportunities
  - 5.1.3.1. New regulations for insulin biosimilars
  - 5.1.3.2. Ongoing investments in R&D of human insulin drugs
- 5.1.4. Challenges
  - 5.1.4.1. Stringent regulatory norms for approvals
5.2. Market Trends
5.3. Cumulative Impact of COVID-19
5.4. Cumulative Impact of Russia-Ukraine Conflict
5.5. Cumulative Impact of High Inflation
5.6. Porter's Five Forces Analysis
- 5.6.1. Threat of New Entrants
- 5.6.2. Threat of Substitutes
- 5.6.3. Bargaining Power of Customers
- 5.6.4. Bargaining Power of Suppliers
- 5.6.5. Industry Rivalry
5.7. Value Chain & Critical Path Analysis
5.8. Regulatory Framework
5.9. Client Customization

6. Human Insulin Drugs Market, by Product Type

6.1. Introduction
6.2. Basal or Long-Acting Insulins
6.3. Biosimilar Insulins
6.4. Combination Insulins
6.5. Fast-Acting Insulins
6.6. Traditional Human Insulins

7. Human Insulin Drugs Market, by Brands

7.1. Introduction
7.2. Humalog
7.3. Lantus
7.4. NovoRapid

8. Human Insulin Drugs Market, by Drugs

8.1. Introduction
8.2. Biologics
8.3. Biosimilars

9. Human Insulin Drugs Market, by Delivery Devices

9.1. Introduction
9.2. Pen Needles
9.3. Pens
9.4. Syringes

10. Human Insulin Drugs Market, by Application

10.1. Introduction
10.2. Type 1 Diabetes
10.3. Type 2 Diabetes

11. Americas Human Insulin Drugs Market

11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States

12. Asia-Pacific Human Insulin Drugs Market

12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam

13. Europe, Middle East & Africa Human Insulin Drugs Market

13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom

14. Competitive Landscape

14.1. FPNV Positioning Matrix
14.2. Market Share Analysis, By Key Player
14.3. Competitive Scenario Analysis, By Key Player

15. List of Company Mentioned

16. Appendix

16.1. Discussion Guide
16.2. License & Pricing